Literature DB >> 11856289

Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center.

Carlo Tascini1, Francesco Menichetti, Silvia Bozza, Monica Fedele, Roberta Preziosi, Massimo Allegrucci, Albano Del Favero, Alessandra Micozzi, Piero Martino, Francesco Bistoni.   

Abstract

OBJECTIVE: To investigate the molecular epidemiology of fluoroquinolone-resistant (FQ-R) and fluoroquinolone-susceptible (FQ-S) bacteremic Escherichia coli isolates from neutropenic patients by pulsed-field gel electrophoresis (PFGE) and random amplified polymorphic DNA (RAPD) analysis.
METHODS: Nineteen FQ-R and 27 FQ-S isolates of E. coli, obtained from patients on a hematologic ward over a 7-year period, were genotyped by PFGE and RAPD using two different random primers (1247 and 1283).
RESULTS: PFGE analysis was able to type all FQ-S isolates and most (17/19, 89%) FQ-R isolates of E. coli. All isolates were genotypically unrelated, with the exception of two indistinguishable FQ-R isolates from different patients in the same period. RAPD analysis typed all isolates, including those FQ-R isolates untypable by PFGE, but was unable to distinguish between some isolates that were different by PFGE. Using primer 1247, RAPD analysis identified six pairs and one triad, while primer 1283 identified seven pairs and one triad of indistinguishable isolates.
CONCLUSIONS: No spread of epidemic FQ-R or FQ-S E. coli isolates was documented among neutropenic patients. RAPD analysis is a powerful genotyping method, but appeared to be less reproducible and discriminatory than PFGE for investigating E. coli isolates.

Entities:  

Year:  1999        PMID: 11856289     DOI: 10.1111/j.1469-0691.1999.tb00175.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

1.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

2.  Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions.

Authors:  Samantha S F Lee; Adrienne E Fulford; Maureen A Quinn; Jamie Seabrook; Irina Rajakumar
Journal:  Support Care Cancer       Date:  2017-11-23       Impact factor: 3.603

Review 3.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

4.  Persistence of Escherichia coli clones and phenotypic and genotypic antibiotic resistance in recurrent urinary tract infections in childhood.

Authors:  Siiri Kõljalg; Kai Truusalu; Inga Vainumäe; Jelena Stsepetova; Epp Sepp; Marika Mikelsaar
Journal:  J Clin Microbiol       Date:  2008-10-29       Impact factor: 5.948

5.  Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials.

Authors:  H Imran; I M Tleyjeh; C A S Arndt; L M Baddour; P J Erwin; C Tsigrelis; N Kabbara; V M Montori
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-16       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.